+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all?

Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all?

World Journal of Gastrointestinal Pharmacology and Therapeutics 2(3): 17-26

Over the past two decades, proton pump inhibitors (PPIs) have emerged as highly effective and relatively safe agents for the treatment of a variety of gastrointestinal disorders. Unfortunately, this desirable pharmacological profile has also contributed to superfluous and widespread use in both the inpatient and outpatient settings. While generally well-tolerated, research published over the last decade has associated these agents with increased risks of Clostridium difficile disease, fractures likely due to calcium malabsorption and both community-acquired (CAP) and hospital-acquired pneumonias (HAP). The mechanism behind PPI-associated pneumonia may be multifactorial, but is thought to stem from compromising the stomach's "acid mantle" against gastric colonization of acid-labile pathogenic bacteria which then may be aspirated. A secondary postulate is that PPIs, through their inhibition of extra-gastric H(+)/K(+)-ATPase enzymes, may reduce the acidity of the upper aerodigestive tract, thus resulting in increased bacterial colonization of the larynx, esophagus and lungs. To date, several retrospective case control studies have been published looking at the association between PPI use and CAP. Some studies found a temporal relationship between PPI exposure and the incidence of pneumonia, but only two could define a dose-response relationship. Furthermore, other studies found an inverse correlation between duration of PPI use and risk of CAP. In terms of HAP, we reviewed two retrospective cohort studies and one prospective study. One retrospective study in a medical ICU found no increased association of HAP in PPI-exposed patients compared to no acid-lowering therapy, while the other in cardiothoracic surgery patients showed a markedly increased risk compared to those receiving H(2)RAs. The one prospective study in ICU patients showed an increased risk of HAP with PPIs, but not with H(2)RAs. In conclusion, the current literature shows a slight trend toward an association between PPI use and pneumonia and an increased risk with PPIs over H(2)RAs, but the findings are not consistent across all studies. Larger controlled trials still need to be done to better identify the risk that PPIs impart towards patients contracting CAP or HAP. Until these are completed, we will have to continue to extrapolate across smaller controlled trials to predict the associated risks in our respective patient populations. In the interim, it appears prudent to limit the use of PPIs to situations where they are clinically indicated and, in such cases, use them at the lowest effective dose. In the case of prescribing for stress ulcer prophylaxis in ICU patients, perhaps H(2)RAs should be used as the preferred agents over PPIs.

(PDF emailed within 0-6 h: $19.90)

Accession: 055260279

Download citation: RISBibTeXText

PMID: 21731913

DOI: 10.4292/wjgpt.v2.i3.17

Related references

Proton pump inhibitor alone vs proton pump inhibitor plus mucosal protective agents for endoscopic submucosal dissection-induced ulcer: a systematic review and meta-analysis. Journal of Clinical Biochemistry and Nutrition 56(2): 85-90, 2015

Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. Journal of Allergy and Clinical Immunology 135(1): 187-197, 2015

The early effect of proton pump inhibitor therapy on the accuracy of the 13C-urea breath test. Digestive and Liver Disease 37(1): 28-32, 2005

Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in the treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine 93(12): E64-E64, 2014

Retraction. Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine 93(29): 399-399, 2015

Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test. Canadian Journal of Gastroenterology 19(6): 350-358, 2005

13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole. Alimentary Pharmacology & Therapeutics 30(3): 294-300, 2010

The effect of proton pump inhibitor on the exhaled breath condensate pH and QOL in QUEST questionnaire-positive asthmatics. Journal of Allergy and Clinical Immunology 119(1-supp-S), 2007

Pathogenesis of proton pump inhibitor induced false negative urea breath test results. Gut 51(Supplement 2): A105, September, 2002

Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease. Respiration; International Review of Thoracic Diseases 74(5): 558-564, 2007

Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS. Digestive Diseases and Sciences 55(8): 2302-2308, 2010

Proton-pump inhibitor use and the risk for community-acquired pneumonia. Annals of Internal Medicine 149(6): 391-398, 2008

Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the [14C]urea breath test. European Journal of Gastroenterology & Hepatology 10(9): 759-764, 1998

An alternate explanation of the effect of citric acid on proton pump inhibitor-associated false negative urea breath tests. American Journal of Gastroenterology 96(10): 3037-3039, 2001

A modified 14C-urea breath test eliminates false negative results in patients taking a proton pump inhibitor. Gastroenterology 118(4 Suppl 2 Part 1): AGA A504, April, 2000